RHEINFELDEN, Switzerland, 22 October 2018 – Tillotts Pharma AG (“Tillotts”) is proud to announce that the poster titled “OPTICORE™: Clinical proof‐of‐concept of colonic‐targeted capsules by pharmaco‐scintigraphy study in healthy human subjects” has been nominated for the Best Abstract Awards 2018 by American Association of Pharmaceutical Scientists (AAPS) Board of Directors.
The AAPS Best Abstract Awards brings attention to the latest, most innovative research based on the abstracts submitted for upcoming AAPS annual meeting, AAPSPharmSci360.
Tillotts’ Poster was selected based on its abstract on the study assessing the in vivo drug release characteristics of OPTICORE™, a novel coating technology combining two triggers for colon targeting (pH and bacterial-enzymatic digestion) and an alkaline middle layer accelerating the dissolution of the pH-responsive outer layer polymer upon water ingress. Drug plasma levels and scintigraphic images data, showing the anatomical location of capsule disintegration and transit in the gastrointestinal tract, will be presented at the AAPSPharmSci360.
“This is a great recognition of our commitment to innovative research in the field of intestinal drug delivery and is the results of the successful collaboration with the Institute of Pharmaceutical Technology, with the Department of Radiology and Nuclear Medicine of the University of Basel as well as the Clinical Trial Unit of the University Hospital Basel.” commented Dr. Roberto Bravo, Head of Pharmaceutical Development at Tillotts Pharma.
AAPS will recognize the winning posters at AAPS PharmSci 360 taking place at the Walter E. Washington Convention Center in Washington, DC on November 4-7 2018. AAPSPharmSci360 connects more than 7000 pharmaceutical scientists from complimentary disciplines, such as chemistry, biology, engineering, and medicine, involved in the discovery, development, and manufacture of pharmaceutical products and therapies that improve global health.
OPTICORE™ stands for OPTImized COlonic RElease. OPTICORE™ is a new, advanced enteric coating, designed to ensure targeted release irrespective of the gut pH variability.1,2 OPTICORE™ uses a unique combination of two triggers – a pH-sensitive and an enzyme-sensitive trigger – designed to release the active ingredient throughout the colon.1 OPTICORE™ has been developed based on the Phloral™ technology.
To learn more about OPTICORE™ visit our website here or watch the video animation
To read the press release in German, please click here
Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 300 employees in Switzerland and abroad. Tillotts is engaged in advancing care and is committed to making a difference for the millions of people worldwide who suffer from GI-diseases.
All trademarks used or mentioned here are protected by law. © Copyright Tillotts Pharma AG. All rights reserved.
Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, operates internationally through a number of subsidiaries in the Ethical Pharmaceuticals and Consumer Healthcare businesses. Zeria is dedicated to research and development of pharmaceutical products and is specialised in the gastroenterology field, among others. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559). Visit their website here
Varum F.O., et al. Poster presented at AAPS National Biotechnology Conference 2016; [Poster number 02W0200]
Ibekwe V.C., et al. A new concept in colonic drug targeting: a combined pH-responsive and bacterially-triggered drug delivery technology. Aliment Pharmacol Ther. 2008; 28(7):911-6.